Therapeutic Potential of TAAR1 Agonists in Schizophrenia: Evidence from Preclinical Models and Clinical Studies

Trace amine-associated receptor 1 (TAAR1) has emerged as a promising therapeutic target for neuropsychiatric disorders due to its ability to modulate monoaminergic and glutamatergic neurotransmission. In particular, agonist compounds have generated interest as potential treatments for schizophrenia...

Descripción completa

Detalles Bibliográficos
Autores principales: Dedic, Nina, Dworak, Heather, Zeni, Courtney, Rutigliano, Grazia, Howes, Oliver D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8704992/
https://www.ncbi.nlm.nih.gov/pubmed/34947997
http://dx.doi.org/10.3390/ijms222413185

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8704992/
https://www.ncbi.nlm.nih.gov/pubmed/34947997
http://dx.doi.org/10.3390/ijms222413185

Ejemplares similares